Realcan Pharmaceutical Group Co., Ltd. sells medicines, medical devices, and medical consumables to medical institutions in China. It operates through the Drug and Equipment Distribution, In Vitro Diagnostics, Pharmaceutical Logistics, Traditional Chinese Medicine, and Microbiome Medicine segments. The company engages in the processing, manufacture, sale, and wholesale of Chinese medicinal materials, herbal medicine, and patent medicine. It is also involved in the wholesale of biochemical, psychotropic, narcotic, and toxic drugs for medical use; chemical APIs, and preparations; antibiotics, biological products, anabolic steroids, peptide hormones, and pharmaceutical precursor chemicals; and medical devices. In addition, the company provides leasing of medical devices and technical services; investment management and consulting services; medical sterilization outsourcing and consulting services; health consulting services; and pharmaceutical logistics services. Further, it engages in the warehousing and distribution of drugs; technology development and transfer; and operation of a health service platform. The company was formerly known as Realcan Pharmaceutical Co., Ltd. and changed its name to Realcan Pharmaceutical Group Co., Ltd. in December 2018. Realcan Pharmaceutical Group Co., Ltd. was founded in 2004 and is based in Yantai, China.
Research context
Realcan Pharmaceutical Group Co., Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Medical Distribution
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Realcan Pharmaceutical Group Co., Ltd is currently in a long term downtrend where the price is trading 11.5% below its 200 day moving average.
From a valuation standpoint, the stock is 97.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.2.
Realcan Pharmaceutical Group Co., Ltd's total revenue sank by 13.4% to $7B since the same quarter in the previous year.
Its net income has increased by 96.9% to $-47M since the same quarter in the previous year.
Finally, its free cash flow grew by 109.2% to $20M since the same quarter in the previous year.
Based on the above factors, Realcan Pharmaceutical Group Co., Ltd gets an overall score of 3/5.